IAN Angel Fund leads Rs 8 Cr funding round in Bengaluru-based startup Biodimension

Company aims to expand across Southeast Asia

IAN Angel Fund, the evergreen fund of IAN Group, has led a Rs 8 crore funding round in Biodimension, a Bengaluru-based life sciences startup specialising in New Approach Methodologies (NAMs) and tissue engineering. Existing investor Campus Angels Network, Dr Sampath Srisailam, also participated in the round along with other angel investors like Aaryan Baid.

The fresh capital will be utilised to accelerate product development, expand laboratory infrastructure, strengthen scientific and commercial teams, and drive product commercialisation in India and international markets.

Founded by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension is building biofabricated human tissue and organoid models as ethical, human-relevant alternatives to animal testing. The company’s solutions help pharmaceutical, biotechnology, and cosmetic companies generate more predictive human data, enabling faster and more reliable decision-making across research, safety testing, and product development.

Despite being one of the world’s largest pharmaceutical manufacturing hubs, India remains dependent on imported human tissue models and testing systems. Biodimension is addressing this gap through locally developed and manufactured alternatives that align with emerging global regulatory standards while offering significantly lower costs and faster access for researchers and industry.

BioDimension’s portfolio includes BioDEpi, a reconstructed human epidermis model for safety and toxicity testing; BioDFT, a full-thickness human skin model that closely replicates real skin biology; BioDPigma, a pigmented skin model designed for advanced dermatological and cosmetic research; the Pan-Cancer Tumour Microenvironment (TME) Biobank, which supports cancer drug discovery and translational research; and BaaS (Bioassay as a Service), enabling pharmaceutical, biotechnology, and cosmetic companies to access validated human-relevant testing solutions on demand.

Biodimension has already established collaborations with pharmaceutical companies, biotechnology firms, research institutions, and contract research organisations across India and Singapore.

Looking ahead, Biodimension plans to expand its Pan-Cancer Tumour Microenvironment Biobank, introduce additional oncology and immunotherapy research models, and strengthen its Bioassay-as-a-Service platform. The company also aims to expand across Southeast Asia while building partnerships in Europe, the United States, and Japan.

Published on : 15th June, 2026